Sex differences in endocannabinoid tone in a pilot study of cannabis use disorder and acute cannabis abstinence
Open Access
- 13 September 2023
- journal article
- research article
- Published by Wiley in Addiction Biology
- Vol. 28 (10) , e13337
Abstract
Cannabis use disorder (CUD) presents differently in men and women, particularly in symptoms of cannabis withdrawal. Novel pharmacotherapeutic interventions for CUD, such as those that target the endocannabinoid (eCB) system, must be developed in a manner consistent with these sex differences. The present pilot study sought to prospectively assess sex differences in cannabis withdrawal in a small sample of adults with moderate‐to‐severe CUD and to determine if withdrawal was associated with peripheral eCB and eCB congener tone. Men and women (n = 5/sex) completed 2 weeks of study participation separated by 1 month; in the latter week, participants abstained from cannabis use. Each week, participants attended in‐person laboratory visits during which blood was drawn repeatedly to assess plasma eCB and eCB congener tone. Participants also completed multiple daily ambulatory assessments to assess cannabis use and withdrawal symptoms. As anticipated, women reported a greater increase in withdrawal symptoms during the abstinent week [Δ = 9.4 (SE = 1.1); p < 0.001] than men [Δ = 1.2 (SE = 1.2); p = 0.35]. Sex differences in levels of the eCB N‐arachidonoylethanolamide (AEA), as well as the eCB congeners stearoylethanolamide (SEA) and linoleylethanolamide (LEA), were evident during abstinence at the morning time point only (p's < 0.05). LEA was associated with withdrawal symptom expression in both sexes [β = 0.16 (SE = 0.09)] and palmitoylethanolamide (PEA) [β = 0.22 (SE = 0.13)] and 2‐arachidonoylglycerol (2‐AG) [β = 0.32 (SE = 0.15)] were associated with withdrawal symptoms in women only. Pharmacotherapeutic development for CUD should consider evident sex differences in eCB and eCB congener tone during abstinence and their associations with cannabis withdrawal, as eCB‐based interventions may produce differential effects by sex.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1‐TR001450)
- National Institute on Drug Abuse (K24‐DA038240, F31‐DA057051, T32‐DA007288, U54‐DA016511)
- Medical University of South Carolina
This publication has 34 references indexed in Scilit:
- Exogenous Delta9-Tetrahydrocannabinol Influences Circulating Endogenous Cannabinoids in HumansJournal of Clinical Psychopharmacology, 2013
- Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography studyMolecular Psychiatry, 2013
- Quantifying the Clinical Significance of Cannabis WithdrawalPLOS ONE, 2012
- The Consensus Sleep Diary: Standardizing Prospective Sleep Self-MonitoringSLEEP, 2012
- Validation of Self-Reported Sleep Against ActigraphyJournal of Epidemiology, 2012
- Increased Blood Pressure After Abrupt Cessation of Daily Cannabis UseJournal of Addiction Medicine, 2011
- Sociodemographic Characteristics of Cannabis Smokers and the Experience of Cannabis WithdrawalThe American Journal of Drug and Alcohol Abuse, 2010
- The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycleFertility and Sterility, 2010
- Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediatorsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2006
- The cannabis withdrawal syndromeCurrent Opinion in Psychiatry, 2006